



ESA 2021 *Annual Report*



The Endocrine Society of Australia

145 Macquarie Street, Sydney NSW 2000
ijohnson@endocrinesociety.org.au
endocrinesociety.org.au

Contents

About the ESA	3
ESA Strategic Plan	4
Board of Directors	8
Reports from the Board	10
Reports from ESA Members	13
Recognition of ESA Members	20
ESA Member's Achievements	25
Award Winners	26
ESA Journals	38
Upcoming ESA Events	40

Who we are

The Endocrine Society of Australia (ESA) is a national non-profit organisation of scientists and clinicians who conduct research and practice in the field of Endocrinology.

The society was founded in 1958 and incorporated in 1986 in the State of Victoria. The Society is governed by the ten members of its Council who are elected every two years by a ballot of the membership in accordance with the Constitution.



Our growth

Our membership continues to grow every year: We currently have 1198 members.

This society is strengthened by its composition of both clinicians and basic science members; and we believe that this true integration of disciplines is one reason for its continued success.

ESA Strategic Plan



Our Mission

The mission of the ESA is to be the premier society in Australia in the field of endocrinology through promoting excellence in research, fostering the integration of clinical and basic sciences, and facilitating the translation of our science to health care and clinical practice.

Key objectives to achieve these goals include the nurturing and developing the future generations of basic and clinical scientists and other health professionals, and the dissemination of new knowledge in endocrinology through our Annual Scientific Meeting and Seminars. The ESA will be proactive in shaping the research and health policies based on scientific advances in our field.



Our Vision

To be recognised as the authoritative voice for endocrinology, endocrinologists and endocrine researchers in Australia and Southeast Asia



Our Purpose

To educate about, engage in, and promote clinical practice and research in endocrinology in the region and world-wide



Our Values

To be knowledgeable, accessible, sustainable and committed

Our Strategic Directions



To promote the education of our current and future endocrinologists and endocrine researchers



To listen to our membership



To maintain financial sustainability for the future



To engage with our members, government bodies, funding bodies and the public to address and resolve issues that affect endocrinology and endocrine research



To promote the profile of the Endocrine Society of Australia



To ensure the governance of the society has continuity of knowledge and expertise

Key Areas of Priority

Education

Objectives

- 1.1. Provide high quality conferences and meetings that attract international and national interest
- 1.2. Provide support for junior members, both clinical and basic scientists, through training, education and scholarships
- 1.3. Support continued training of high quality endocrinologists through work force planning and addressing issues affecting training

Profile

Objectives

- 2.1. Promote endocrinology within Australia via our branding
- 2.2. Provide education, networking opportunities and showcase our research
- 2.3. Promote our expert members both nationally and internationally
- 2.4. Be recognised as the authoritative voice for endocrinology, rare endocrine disorders and obesity in Australia and the region

Governance

Objectives

- 3.1. Maintain a highly skilled and motivated board
- 3.2. Source skilled, motivated and committed consultants with clearly defined roles to drive our objectives
- 3.3. Have the right committees with the right people to deliver strategic objectives
- 3.4. Educate board members in governance so our strategic ability and decision making is enhanced

Internal Engagement: Membership

Objectives

- 4.1. Hear the needs of our members
- 4.2. Retain and ensure sustainability of our expertise within the membership
- 4.3. Communicate and engage other endocrine based societies to increase membership both nationally and internationally
- 4.4. Ensure ESA members are assisting ESA to reach its objectives

External Engagement

Objectives

- 5.1. Engage consistently with the RACP for endocrinology training, secretariat business and endocrine advocacy
- 5.2. Engage with industry for sponsorship and financial sustainability
- 5.3. Engage with Government for addressing endocrine issues that affect ESA sustainability and profile
- 5.4. Engage with the NHMRC at every possible level to promote the funding of endocrine research, for endocrine advocacy and for the joint production of position statements
- 5.5. Engage with the public via the media to enhance the ESA profile and opportunities for bequests
- 5.6. Increase our presence and effectiveness on other boards and panels of institutions

Financial Sustainability

Objectives

- 6.1. Achieve a sufficient and more reliable income stream through investments, industry, bequests and conferences
- 6.2. Maintain a productive operating budget
- 6.3. Maintain long term financial sustainability of the scholarship programs

Board of Directors



**Professor Bu Beng Yeap
(President)**

Medical School, University of Western Australia | Department of Endocrinology and Diabetes, Fiona Stanley Hospital, Perth, WA



**Associate Professor Timothy J. Cole
(Past President until 21/11/2021)**

Department of Biochemistry & Molecular Monash University, VIC



Dr Belinda A. Henry (Treasurer)

Research Fellow
Department of Physiology
Monash University, VIC



**Professor Mathis Grossmann
(Honorary Secretary)**

University of Melbourne, Austin Health, VIC



**Associate Professor Ann McCormack
(President Elect)**

Staff Specialist, Department of Endocrinology, St Vincent's Hospital | Head, Hormones & Cancer Group, Garvan Institute of Medical Research, NSW

Associate Professor (Peter) Shane Hamblin

Department of Endocrinology & Diabetes
Western Health, Sunshine Hospital, VIC



Associate Professor Diana Learoyd

University of Sydney, Northern Clinical School,
Faculty of Medicine and Health, NSW



Dr Emily Mackenzie

Department of Diabetes and Endocrinology
Princess Alexandra Hospital
Woolloongabba QLD



Associate Professor Frances Milat

Endocrinologist & Deputy Director of Endocrinology,
Monash Health. Head, Metabolic Bone Services,
Monash Health. Head, Metabolic Bone Research
Group, Hudson Institute of Medical Research. Adjunct
Associate Professor, School of Clinical Sciences,
Monash University, VIC



Dr Ada Cheung

Endocrinologist
NHMRC Research Fellow | Department of Medicine
(Austin Health) | The University of Melbourne, VIC



Ivone Johnson

Secretariat, Executive Officer
145 Macquarie Street Sydney, NSW
e: ijohnson@endocrinesociety.org.au



Melissa Dupavillon

Administrative Assistant
145 Macquarie Street Sydney, NSW



President's Report

This is the second year that the Annual Scientific Meeting and the AGM have been held online. All of us acknowledge the impact of COVID-19 goes far beyond disrupting travel and face-to-face meetings.

Globally, COVID-19 has caused millions of infections, hospitalisations and deaths. In Australia we have had multiple lockdowns across States and Territories, despite which we have experienced a resurgence of COVID-19 with hospitalisations and deaths, and stresses on our community and health sector. ESA members have stood up to help shoulder the COVID-19 burden, as clinicians and researchers. During this time, ESA continues to support its members, providing research postdoctoral awards and seeding grants, and educational opportunities via virtual Seminar, Clinical Weekend and Annual Scientific Meetings. To the best of our ability, we have created opportunities to discover and share new knowledge, helping achieve optimal outcomes for people with endocrine and related medical conditions.

Earlier this year, we highlighted via an e-bulletin that Council were reviewing ESA's Constitution. ESA's original founding documents date back to 1958, with the Constitution amended in 2005. Our auditor had expressed concern as to whether these documents adequately defined ESA's tax exempt status, a potential vulnerability for ESA. Council embraced the opportunity to update ESA's Constitution to clarify our status as a health promotion charity, able to receive tax-deductible donations. The new Constitution

provided a timely opportunity to restate ESA's main goal, to promote the prevention, control and optimal treatment of endocrine and related medical conditions. ESA aims to advance endocrine science, improve clinical practice, and support its members. We will nurture future generations of endocrinologists and endocrine scientists, share our expertise, disseminate new knowledge, and work with other endocrine societies who share these purposes.

Other important issues identified over the years have been addressed. Instead of 8 elected members, Council will now have 10 5 elected every 2 years for four year terms. There will be at least 3 endocrinologists and at least 3 basic scientists on Council, representing ESA's two major membership groups. We will have representation across States and Territories, with 3 Councillors from Victoria/Tasmania, 3 from NSW/ACT, 2 from QLD/NT, 1 from SA and 1 from WA. We will also specify gender balance, with no more than 7 Councillors of any one gender. The new Constitution was drafted with the help of legal advisors, with extensive input from Council members and Past-President Warrick Inder. Within the AGM agenda and notices is a Special Resolution that the new Constitution be adopted by the ESA.

I am able to share an exciting piece of news. ESA was informed early this year of a very generous bequest made by the late Robert Archibald Burns, creating the RA Burns Trust to be administered by State Trustees of Victoria. Annual income from this Trust will be distributed via ESA to support pituitary hormone research

in Australia. The Trust is likely to be established in 2022, thus ESA anticipates making the first call for research proposals to be funded via this bequest in 2023, adding to our existing ESA post-doctoral and Ken Wynne awards. I would like to acknowledge the late Robert Burns' tremendous altruism and generosity. I am confident these funds will support vital research.

I would like to acknowledge all ESA members who contribute their time, energy and expertise.

Thanks to my fellow Councillors for their work on behalf of ESA, especially Belinda Henry our Treasurer, and Mathis Grossmann our Honorary Secretary. Thanks also to the Medical Affairs Committee led by President-elect Ann McCormack and Emily Mackenzie, who provide endocrine expertise and policy guidance to other organisations and government bodies, and Sunita De Sousa and Liz Johnstone who lead the ESA Early Careers Committee. Thanks to fellow Councillors Shane Hamblin, Di Learoyd, Ada Cheung, Fran Milat, and Past-President Tim Cole, and to ESA stalwarts Duncan Topliss, John Walsh, and many others for their valued contributions throughout the year. Special thanks to Helen Barrett and Mitchell Lawrence, the ESA co-chairs of the ASM POC, and the members of the POC for organising this year's successful virtual ASM, Lachlan Angus and his LOC for

organising this year's clinical weekend, and Di Learoyd and Anna Story for our Seminar earlier in the year. Thank you to Nicki Hodyl (ably assisted by Belinda Henry, Tim Cole and others) who oversaw the creation of ESA's public-facing Hormones Australia website, and modernised ESA's own primary website. Thanks also to our efficient and effective Secretariat and our Executive Officer, Ivone Johnson, and to Jim Fawcett and the ASN Events team.

May I offer ESA's deepest congratulations to Ken Ho who was awarded a (US) Endocrine Society Laureate Award 2022, the Outstanding Scholarly Physician award, and to Peter Ebeling, incoming President of the American Society for Bone and Mineral Research. I was also delighted to announce the receipt of nominations of ESA Honorary Life Membership for Helena Teede, Vicki Clifton and Chen Chen. I hope all of you will join me in acknowledging the outstanding contributions they have made to ESA and to research and practice of endocrinology over the years.

Best wishes to everyone, and please stay safe and well. I look forward to catching up, hopefully face-to-face at the ESA Seminar meeting in Launceston and the ASM in Christchurch in 2022.



Bu Yeap
President

Treasurer's Report



Operating Results

Net profit of \$248,153

This is compared to a profit of \$112,086 (2019) and loss of \$120,916 (2020).

Seminar Weekend	\$30,185.42
Clinical Weekend	\$5000 (projected)
ASM	\$40,000 (projected)
Total Surplus	\$75,185.42

Asgard Accounts

There are two funds managed by Jason Dix (Carrington Financial Services). We have seen a strong recovery of both of investment accounts after the global down-turn that occurred in March 2020.

The Endocrine Portfolio

Balance at 29/10/2020: \$1,281,569

Balance at 20/10/2021: \$1,444,293

The Wynne Portfolio

Balance at 29/10/2020: \$780,104

Balance at 20/10/2021: \$844,625

Membership

Increase in membership to 1198 from 856 in 2020.

Accounts held at the National Australia Bank

Working account:

Balance at 20/10/21: \$176,670

Two fixed term deposits:

Balance at 20/10/2021: \$127,190 and \$96,324

Current value of Societies net assets: \$2,769,457 compared to \$2,478,595 in 2020

Awards

ESA is dedicated to ensuring that we provide financial support in the form of scholarships, fellowships and awards. In the past financial year, we have provided \$136,500 in award funding to our members. In 2021 we have not provided travel awards due to travel restrictions; these will resume in 2022.



Belinda Henry
Treasurer

ESA/SRB/ANZBMS ASM Report

Due to the COVID-19 pandemic, the ESA/SRB/ANZBMS ASM meeting planned for Melbourne was converted to a virtual meeting.

The Clinical Weekend and ASM are planned for the 20th - 24th November were converted to purely online formats.

We were delighted to include Professor Wiebke Arlt from the University of Birmingham as the Harrison Lecturer, and Professor Mirjam Christ-Crain as the Taft Lecturer. Other highlights of the meeting included an Early Career workshop with presentations from members across the society sharing their advice and expertise with our trainees and junior scientists.

The themes for this year included Diabetes (marking the 100th anniversary of Bunting and Best), Adrenal, Neuroendocrine Control of Behaviour, Endocrine Disrupting Chemicals (joint with SRB on the 30th anniversary of the term EDC), Sport and Endocrine Disorders (joint with ANZBMS), and Transgender Health (also joint with

ANZBMS). Our Hot Topics session focused on COVID-19 to ensure we were up to date on this evolving area. Lunchtime forums included a T4DM panel and meet-the-expert sessions on bone and hormone-dependent cancers.

There were 839 registrations for the ASM. Sponsorship was strong, with a total of \$144,898 in sponsorship confirmed so far for the three societies.

We would like to thank ESA Council, Ivone Johnson, the POC and LOC committee members, as well as ASN events for their support.



Helen Barrett
ESA POC Co-Chair



Mitchell Lawrence
ESA POC Co-Chair

Medical Affairs Committee Report

As in previous years, the ESA Medical Affairs Committee (MAC) continues to be actively involved in many consultative and advocacy projects responding to requests from RACP, Department of Health and many other national groups.

TGA Medicine Shortages Taskforce and Consultation Paper

In response to a number of ESA members expressing concern about supply of critical endocrine therapies such as carbimazole and desmopressin during 2020/21, ESA MAC worked with the newly created TGA Medicines Shortages Taskforce resulting in a number of high level actions and fast-tracking of alternative formulations under Section 19A of the Therapeutic Goods Act. Subsequently ESA MAC participated in a TGA consultation paper on “Building a more robust medicine supply”.

National Medicines Policy Framework

The Department of Health has recently launched a Review of the National Medicines Policy. ESA MAC provided a response to a discussion paper highlighting concerns around building capability in supply chains to avoid critical shortages as experienced during the pandemic and expressing need for more oversight of medical devices, biosimilars and supplements in the marketplace. We will also have representation on an upcoming group consultation.

Guideline Development Working Party representations

ESA MAC provided nominations to the following guideline development working parties: Australian New Zealand Hypophosphatemia Management (Dr Syndia Lazarus), Tumour-Induced Osteomalacia (A/ Professor Rory Clifton-Bligh), Sun Exposure Summit Roundtable (Dr Christian Girgis), Growth Hormone Research Society Safety of GH treatment in Cancer Survivors (A/ Professor Ann McCormack).

RACP

RACP consulted ESA MAC on a number of issues including advice to Minister Hunt around treatment of gender dysphoria in children and adolescents, feedback on the future role of telehealth and on the RACP Advanced Trainee Selection and Matching Service. In addition, ESA members Dr Venessa Tsang and Dr Matti Gild provided 2 excellent webinars hosted by RACP.

Equality Australia consultation regarding Victorian intersex oversight panel proposal

Equality Australia approached ESA MAC regarding a proposal to the Victorian government to assist them in developing an oversight panel to ensure compliance with a mechanism to prohibit deferrable medical interventions on intersex people without personal consent.

ESA MAC's feedback focussed on ensuring medical professional oversight on the panel and wider consultation from key stakeholders on any proposal including surgeons, urologists and paediatricians.

Endorsements

ESA MAC has provided endorsement of a position statement on Primary Hyperparathyroidism in Adults, a proposal to update NHMRC Clinical Practice Guidelines for the management of overweight and obesity and a National Action Plan for NeuroEndocrine Tumours.

ESA MAC provided endorsement on a 2021 Primary Aldosteronism Centre of Excellence (PACE) grant proposal. ESA MAC advised RACP to decline endorsement on a Clinical Guideline on the Management of Erectile Dysfunction.

Acknowledgements

Thank you to all ESA MAC members, and other ESA members who have contributed expertise when approached. I am grateful for the combined support of colleagues that has produced very meaningful contributions of ESA to the wider community.

Thanks to ESA MAC team: Di Learoyd, Mathis Grossman, Shane Hamblin, Ada Cheung, Fran Milat, Emily Mackenzie, John Walsh and Leon Bach. Finally thank you to Ivone Johnson, our wonderful Executive Officer who is so experienced in all the workings of ESA.



Emily Mackenzie
ESA MAC Co-chair



Ann McCormack
ESA MAC Co-chair

ESA Seminar Meeting

ESA Seminar was cancelled in 2020, in the face of the then new COVID-19 virus.

With the academic and social programme all set to go, we plan to deliver that program in Launceston in 2022. In light of the ongoing uncertainty about travel, and in particular international travel for our plenary speaker Prof. Gary Hammer, this will be in a hybrid format, with the option for face to face or virtual registration.

The social programme is being revised currently with the benefit of new opportunities in historic Launceston to allow for an anticipated 300 delegates face to face.

ASN Events is to be congratulated for a smooth platform that all delegates agreed ensured an enjoyable meeting despite the virtual format.

ESA is grateful for the generous pharma sponsorship that, along with registrations, generated a healthy profit of \$30,185.42 for 2021, offsetting some the loss of the COVID-cancelled 2020 seminar.



Anna Story
Co-convener

The Seminar in 2021 was a virtual event with a record number of 571 registrants.



Diana Learoyd
Co-convener

The main theme was pituitary disease, and the plenary speaker was Prof. Gudmundur Johannsson from Gothenburg Sweden. Talks from local pituitary experts were supplemented with great cases and with the general interest topics of thyroid nodules, hypothalamic amenorrhoea and obesity.

Clinical Weekend

Due to the Victorian COVID-19 restrictions and uncertainty around border closures, the decision was made to change from a hybrid to fully virtual meeting format for the ESA Clinical Weekend to be held on 20-21 November 2021.

This year's program featured 15 registrar case presentations covering themes of pituitary, adrenal, reproductive endocrinology and metabolic bone disease, in collaboration with ANZBMS.

We were fortunate to have guest plenary speakers including Prof Wiebke Arlt, Prof Mirjam Christ-Crain and Dr Nandini Shankara Narayana deliver live presentations on the management of adrenal insufficiency/ congenital adrenal hyperplasia, diabetes insipidus and androgen abuse respectively.

As of 21 October 2021, we had 332 registrations and had obtained \$8,800 in sponsorship from Amgen and Ipsen, which will allow the meeting to, at minimum, break even. We received 53 case submissions for review.

I would like to thank the organising committee, case reviewers, session chairs and judges for volunteering their time as well as the ESA Council, Ivone Johnson, and ASN Events for their support.



Lachlan Angus
Convener

Early Career Committee Report

The inaugural ESA Early Career Committee (ECC) was formed in August 2019, and currently consists of seven early career members (ECMs) appointed by ESA Council. The aim of the ECC is to help advance the clinical and research endeavours of ECMs by creating professional development activities, expanding research opportunities, fostering participation of ECMs within ESA, and facilitating interaction between junior and senior members.

At the ESA Virtual ASM 2020, we held a successful Early Career Development Workshop entitled 'Careers in Endocrine Research and Clinical Practice'. This session was chaired by Dr Sunita De Sousa and Dr Liz Johnstone, and had five speakers: Prof Kevin Pflieger (WA), A/Prof Nicolette Hodyl (Vic), Dr Ada Cheung (Vic), Dr Ailie Connell (Vic) and Dr Anna Story (NSW). The final number of delegate registrations was 183.

We went on to host another virtual ECM workshop at the ESA Seminar in May 2021, entitled 'Starting a Research Career'. The audience heard from Dr Anju Johan (Vic), Dr Mark Fui (Vic) and Dr Claire Morbey (NSW), each reflecting on their different pathways in research. Session chairs, Dr Alicia Jones and Dr Kanaka Jeyaraman moderated the lively discussion through the workshop.

Another recent initiative of the ECC is the ESA Subspecialist Network which was launched in the new ESA website earlier this year in

collaboration with the ESA Council. The aim of this online directory is to enable junior clinicians to contact subspecialists across Australia in order to obtain general comments and discussion in complex cases. With 35 experts currently listed across 14 different subspecialties, we hope to build the network in the years to come.

At this year's joint ESA/SRB/ANZBMS Virtual ASM, we are organising two Early Career sessions, in collaboration with ECMs from the two other societies.

1 The first is a Panel Session co-organised by all three societies. The session is titled "Building collaborations and networking – the keys to a successful career", and each society has invited one speaker, each speaker with a different focus, either clinician, industry or academia focussed.

We have invited Prof Helena Teede (Vic) to speak about her extensive career as a clinician-scientist, while SRB has invited Prof Neil Gemmell (NZ) to give his perspective as an academic and ANZBMS has invited Dr Sandra Iuliano to speak from the perspective of an academic with experience working in/with industry. Following the speaker's presentations there will be a question and answer session with our online ECM audience. Currently, the Panel Session has 415 registrations.

2

The second session we are organising is a speed networking event called “Science at Speed: a meeting of the minds”, and we are co-organising this with ANZBMS.

This event aims to foster collaboration and networking across different disciplines and career levels, by pairing people from different backgrounds and giving them 6 minutes to pitch their research and/or career interests. Participants then move on to a new pair, allowing networking with 10 different people over the hour-long session. This session currently has 221 registrants.

At the ASM this year, four of our members will come to the end of their two-year term: Nicholas Russell (Vic), Thaw Htet (NSW), Sahar Keshvari (Qld) and Kanakamani Jeyaraman (NT). The remaining three members are staying on for a third year to provide continuity: Sunita De Sousa (SA), Liz Johnstone (WA) and Alicia Jones (Vic).

We sent out a request for expressions of interest and received many highly competitive applications. The applications were judged and scored in collaboration with members from ESA Council and the five highest ranking applicants were awarded positions on the committee.

These new committee members are: Alexander Rodriguez (Qld), Matti Gild (NSW), Annabelle Warren (Vic), Emily Brooks (Qld) and Lachlan Angus (Vic). The committee will continue to have a balanced representation of scientists and clinical endocrinologists, gender and location.

We thank our outgoing committee members for their service and look forward to welcoming our new members at this year’s ASM. Looking forward to next year, we hope to finally be able to hold our first face-to-face workshops at the Seminar Weekend and the 2022 ASM.



Elizabeth Johnstone
Scientific Chair of the
Early Career Committee



Sunita De Sousa
Clinical Chair of the Early
Career Committee

Recognition of ESA Members

Congratulations to ESA Life Members...



Chen Chen

Professor Chen Chen MBBS, MD, PhD, is a Chair Professor of Endocrinology and Physiology at University of Queensland and was NHMRC Fellow (RF, SRF, PRF) from 1996-2013.

He is head of Endocrinology and Metabolism at School of Biomedical Sciences, UQ and was head of Endocrine Cell Biology at Prince Henry's Institute of Medical Research till 2008 (now Hudson Institute of Medical Research), Melbourne.

Chen pioneered the membrane ion channel study in pituitary endocrine cells, which allowed analysis of single cell signalling molecules and receptors in the regulation of hormone exocytosis.

His laboratory investigated neuroendocrine hormone secretion profiles and correlation with metabolic regulatory hormones, such as insulin, ghrelin, leptin, adiponectin, etc. in relation to metabolic disorders animal models of sheep, rat, and mouse.

Chen has also made significant contributions to our understanding

of the influence that stress, metabolic states, circadian, ageing, and gender, on neuroendocrine and metabolic hormones and metabolic balance. His research is closely related to pathophysiology of obesity (and related diseases), diabetes, and ageing.

Chen has over 280 peer-reviewed publications in endocrine related journals and contributed to Australian endocrinology through membership of ESA and ESA Council for many years. He has been a member of editorial boards for Endocrinology, Molecular and Cellular Endocrinology, Endocrine, and other more than 10 international journals.



Helena Teede

Professor Helena Teede MBBS, FRACP, PhD, FAAHMS holds leadership roles across health care, research and policy including as the Director of Monash Centre for Health Research Implementation, School of Public Health and co-director of the Monash Institute of Medical Engineering Monash University, an Endocrinologist at Monash Health, and Executive Director of Monash Partners Academic Health Sciences Centre.

Helena has had an active 20 year academic career, supported by NHMRC fellowship funding. Helena was an ESA Council Member from 2008-2016, and was ESA President from 2014 to 2016.

Professor Teede's research interests focus on women's health during the reproductive years, and on metabolic health including obesity and its endocrine, reproductive and metabolic complications such as PCOS, infertility, pregnancy complications, gestational diabetes and diabetes.

She is strongly committed to stakeholder engagement in health promotion, healthcare improvement, implementation research and health service / systems innovation across different settings and populations.

Helena has co-designed, delivered and scaled Women in Leadership Capacity Building Programs for over a decade.

Her research is actively translated into guidelines and resources now actively accessed and supporting care in 126 countries.



Vicki Clifton

Professor Vicki Clifton PhD

GAICD, FRSM is a National Health and Medical Research Council Research Fellow (2000-2022) and a Professorial Research Fellow with Mater Research Institute and The University of Queensland.

Vicki is internationally recognised for her research on the impact of maternal asthma and other health complications during pregnancy on maternal well-being, placental function, fetal growth and childhood development with a particular focus on glucocorticoid regulated pathways.

Her research has contributed to changes in clinical practice for the management of asthma during pregnancy and the rewriting of numerous practice guidelines.

Vicki was employed at the Robinson Research Institute at the University of Adelaide from January 2008 to April 2015 after many years at the Mothers and Babies Research Centre in Newcastle, Australia (1990-2007).

While at the Robinson Research Institute she was Director of Clinical Research at the Lyell McEwin Hospital in Adelaide, Australia (2009-2014).

Vicki attended her first Endocrine Society of Australia meeting in

1990 and has been a member since then. In 2004 she was appointed Treasurer of ESA Council and held this position until 2010 when she subsequently became the first female President of the Endocrine Society of Australia (2011-2013).

She was the first female Editor of the Placenta Journal (2012-2018). She was an Executive member of the International Society of Endocrinology Board (2016-2020) and has held numerous Governance and Board memberships throughout her career.

ESA Member's Achievements

Endocrine Society 2022 Laureate Award



Ken Ho

Professor Ho is Emeritus Professor at the Garvan Institute, University of NSW and Honorary Consultant Endocrinologist, St. Vincent's Hospital in Sydney, Australia.

As a globally recognised pituitary medicine expert and leader in academic clinical endocrinology, he has developed therapeutic guidelines and advocated for regulatory agency decisions geared to improving patient outcomes.

He established a gold-standard diagnostic test for growth hormone (GH) deficiency and developed standards for use of GH replacement therapy in adults.

He has published over 250 peer-reviewed studies that directly impact clinical practice. He currently serves as Associate Editor for the Journal of the Endocrine Society and as a member of the Society's Nominating Committee.

RACP Fellows Research Establishment Fellowship



Ada Cheung

Dr Ada Cheung is an endocrinologist at Austin Health and an NHMRC and Dame Kate Campbell research fellow at The University of Melbourne. She leads the Trans Health Research group which aims to provide robust evidence to improve the health and wellbeing of the trans community.

Her research findings have contributed to the investment in two new multidisciplinary gender clinics in Victoria and a statewide training program for health professionals in trans health and new national guidelines in the

hormonal management of trans and gender diverse individuals. Ada has won a number of national and international awards for her research, including being the only Australian to win a US Endocrine Society Early Investigator Award and the ESA Bryan Hudson Clinical Endocrinology Award.

This fellowship will support Ada to investigate the 'Safety of transdermal estradiol in transgender women during surgery — a randomised double-blind placebo controlled trial'.

Australia Day Honours



OFFICER (AO) IN THE GENERAL DIVISION

Professor Susan Ruth Davis
For distinguished service to medicine, to women's health as a clinical endocrinologist and researcher, and to medical education.



OFFICER (AO) IN THE GENERAL DIVISION

Professor Peter Jeffery Leedman
For distinguished service to medicine, health and medical research as a physician-scientist, to professional societies, and to tertiary education.



MEMBER (AM) IN THE GENERAL DIVISION

Professor Jonathan William Serpell
For significant service to medicine, particularly to endocrine surgery.

Queen's Birthday 2021 Honours



MEMBER IN THE GENERAL DIVISION (AM)

Professor Helena Teede
For significant service to medical education and research, to endocrinology, and to women's health.



HONORARY MEMBER (AM) IN THE GENERAL DIVISION

Dr Frank Peter Alford
For service to endocrinology.

Members Passing



Vale: Dr Philip Ernest Harding (1941-2021) AM. BSc Med. MB BS. FRACP

Dr Philip Harding passed away on 25th May succumbing to a malignant brain tumour.

Philip was a former Director of the Department of Endocrinology in the Royal Adelaide Hospital from 1976 to 1996, and from then a Visiting Consultant Endocrinologist until 2003, and thereafter Emeritus Consultant in Endocrinology.

Philip was elected to the Council of the ESA in 1974 and was the Honorary Secretary of the ESA

1976-1978. He was also Editor of the Proceedings of the Annual Scientific Meetings and the Honorary Archivist of the ESA from 1976 to 1992. He was made an Honorary Life Member of ESA in 2002.

Philip made significant contributions to many different medical and scientific organisations at both State and National levels including the Australian Diabetes Society, the RACP, the TGA, Chairman of Medical Staff at Royal Adelaide Hospital and President of the SA branch of the AMA. He was awarded an AM in the Order of Australia in 2017.



Vale: Dr Min Ling

The endocrine community has lost a valued colleague and friend. Dr Min Ling, an endocrinologist in NSW, has worked with many over the years in private practice, as well as at Macquarie University, Ryde, Hornsby and Nepean Hospitals.

She trained at Royal Prince Alfred, Newcastle, Bankstown and Nepean hospitals.

She passed away after a short illness. Our thoughts are with her long-time partner, Lee and her family in China.

Her friendship will be treasured by many and she will be remembered for her generosity of spirit, kind nature and devotion to the practice of endocrinology.

Award Winners



ESA Mid Career Research Award

Anju Joham



ESA-Novartis Junior Scientist Award

Bronia Harding-Davis



Bryan Hudson Clinical Endocrinology Award Winner

Sarah Catford



ESA Paul Lee Best Abstract Award

Valentina Rodriguez Paris



ESA Outstanding Clinical Practitioner Award

Warrick Inder



ESA Outstanding Clinical Practitioner Award

Roderick Clifton-Bligh

**ESA Australian Women in Endocrinology
Outstanding Abstract Award**

Kelly Walton



**ESA Australian Women in Endocrinology
Outstanding Abstract Award**

Jennifer Chen



**ESA Australian Women in Endocrinology
Outstanding Abstract Award**

Ayanthi Wijewardene



**ESA Australian Women in Endocrinology
Outstanding Abstract Award**

Caroline Jung



**ESA Young Investigator Scientific Article
Award (Basic Science)**

Adam Hagg



**ESA Young Investigator Scientific Article
Award (Clinical)**

Mark Ng Tang Fui



**Bioscientifica-EDM-Case Reports
Best Case Report**

Huajing Ni



Award Winners



ESA Research Seed Grants

Ann McCormack



ESA Research Seed Grants

Nicholas Russell



ESA Research Seed Grants

Diane Rebourcet



ESA Research Seed Grants

Varun Venkatesh



Best Basic Science Poster

Nicholas Choo



Best Clinical Study Poster

Elisabeth Ng

ESA Postdoctoral Award - 2020

Emily Brooks



ESA Research Higher Degree Scholarship - 2020

Amanda Seabrook



ESA Ken Wynne Memorial Postdoctoral Research Award - 2020

Aneta Stefandis



ESA Research Higher Degree Scholarship - 2021

Ayanthi Wijewardene



ESA Ken Wynne Memorial Postdoctoral Research Award-2021

Sarah Glastras



RACP Endocrine Society of Australia (ESA) Research Establishment Fellowship in Endocrinology 2021

Stephanie Johnson



ESA Young Investigator Scientific Article Award

The ESA Young Investigator Scientific Article Award is made annually to recognise the best scientific paper published in the 12-month period preceding the closing date for abstracts for the Annual Scientific Meeting by an active member of the Endocrine Society of Australia early in their career.

Recipient: Adam Hagg



It is an honour to be the recipient of the ESA Young Investigator Basic Scientific Article Award 2021 for our team's manuscript titled 'Perturbed BMP signaling and denervation promote

muscle wasting in cancer cachexia' published in *Science Translational Medicine* (DOI: 10.1126/scitranslmed.aay9592).

Thank you to ESA for the recognition of our work and for the opportunity to present the story at this year's annual scientific meeting. This work was completed as part of an international collaboration that formed part of my PhD studies. Our work has focused on identifying novel cellular mechanisms that control skeletal muscle mass in the setting of cancer associated muscle wasting.

The majority of cancer patients suffer muscle weakness and frailty associated with tumor burden: this is known as cancer cachexia. One in three advanced cancer patients die from complications associated with cachexia. There are no effective treatments for this condition. Our manuscript demonstrates that tumour and host derived factors such as Interleukin 6 and Activin A, act to inhibit the Bone Morphogenetic Protein (BMP)

signalling pathway in the skeletal muscle of tumour-bearing mice, causing muscle atrophy and remodeling of the neuromuscular junction. Furthermore, we show that the compound Tilorone, a BMP activator, restores BMP signalling in skeletal muscle when administered to tumour-bearing mice, reducing cachexia and extending lifespan. Our recent findings identifying novel cellular mechanisms that underpin the pathogenesis of cachexia and have important implications for pre-clinical and clinical cachexia studies in the future.

I am extremely grateful for this award and the support from the ESA throughout my career to date. I'd also like to recognise the contributions of my PhD supervisors, A/Prof. Paul Gregorevic and A/Prof. Craig Harrison, as well as our collaborators Dr. Roberta Sartori and Prof. Marco Sandri at the Venetian Institute of Molecular Medicine & University of Padova, Italy.

ESA Young Investigator Scientific Article Award

The ESA Young Investigator Scientific Article Award is made annually to recognise the best scientific paper published in the 12-month period preceding the closing date for abstracts for the Annual Scientific Meeting by an active member of the Endocrine Society of Australia early in their career.

Recipient: Mark Ng Tang Fui

AWARD WINNERS



I am honoured to receive the 2021 ESA Young Investigator Scientific Clinical Award for the publication in the JCEM “Effect of testosterone treatment on bone microarchitecture and bone mineral density

in men, a 2 year RCT” (T4 bone). I am also grateful to ESA and RACP for supporting this work with the 2018 inaugural research establishment scholarship.

To date, the role of testosterone treatment in middle-aged and older men with comorbidities such as obesity and insulin resistance but without classical hypogonadism, remains unclear. The 2 year T4 bone study and its parent RCT T4DM are landmark papers in this field. The T4 bone is the first RCT to report that testosterone treatment in overweight men improves bone microarchitecture, as measured by high resolution peripheral quantitative CT (HR-pqCT), with improvements particularly in cortical bone, and is the first testosterone trial powered to report beneficial effects of testosterone treatment on hip bone mineral density, as measured by DEXA. T4Bone is also notable as the largest testosterone treatment randomised controlled trial reporting on bone outcomes, including 177 men who underwent

high-resolution HR-pqCT and 601 men who underwent bone density by DEXA. T4 bone was made possible due to the collaboration of 5 Australian academic centres.

Whilst T4 bone has established the beneficial effects of testosterone treatment on bone microarchitecture and bone mineral density, with treatment effects of testosterone in men comparable to treatment effects of established osteoporosis treatments in RCTs studying postmenopausal women, a number of questions still remain, including whether testosterone treatment reduces fracture risk in middle-aged and older men. Larger and longer trials are required to establish this.

I am grateful to my supervisor Professor Mathis Grossmann and would also like to thank the academic leads at the T4 bone study centres around Australia. I was both humbled and honoured to be invited to participate in this landmark trial with thanks to Professor Gary Wittert who led the T4DM study. Thank you again to the Endocrine Society of Australia for this award and also for supporting me with other awards and grants previously.

ESA Mid-Career Research Award

This award is designed to recognise an outstanding mid-career researcher in endocrinology.

Recipient: Dr Anju Joham



It was a tremendous honour to be awarded the Mid Career Award from the Endocrine Society of Australia. I thank the ESA for this award and also for the opportunity to present my work at previous ESA meetings

over previous years.

In my presentation, titled “Polycystic Ovary Syndrome: insulin resistance and data from cohort studies”, I presented my doctoral study results involving a mechanistic insulin resistance study that examined insulin resistance in lean and obese women with PCOS compared to controls. Women with PCOS were more insulin resistant than body mass index (BMI)-matched controls on euglycaemic hyperinsulinaemic clamp studies. Insulin resistance was present in 75% of lean women with PCOS, 62% of overweight controls and 95% of overweight women with PCOS. This study demonstrated that even lean women with PCOS exhibit an intrinsic insulin resistance that may then be exacerbated by extrinsic / lifestyle related insulin resistance seen in overweight / obese women with PCOS.

As part of my doctoral and postdoctoral studies, I have examined large epidemiological datasets to further understand the natural history of PCOS as there is a lack of

community-based studies exploring the natural history of PCOS. The Australian Longitudinal Study on Women’s Health (ALSWH) is a large community-based prospective study, with data from approximately 9,000 reproductive-aged women at seven time points over 19 years. The Raine cohort from WA (2,868 pregnant women with long-term follow-up) is one of the largest prospective cohorts of childhood, adolescence, and pregnancy in the world. Data have been collected at 11 time points over 26 years, including clinical data, bloods and imaging. I presented data on reproductive, metabolic and psychological outcomes from both a cross-sectional and longitudinal analysis from the above datasets.

I would like to acknowledge my mentor and supervisor, Prof Helena Teede, for her invaluable guidance throughout my career. I would also like to thank the PhD students from the PCOS Epidemiology stream from the Monash Centre of Health Research and Implementation, Monash University, in particular Dr Jillian Tay, Ms Sylvia Kiconco and Dr Nadira Kakoly for contributing to this body of work and the epidemiologists at MCHRI for their guidance. I also acknowledge funding from the National Health and Medical Research Foundation through a NHMRC Postgraduate Scholarship and Early Career Fellowship, a Bridging Fellowship from SPHPM, a seed grant from CRE PCOS and a Fellowship from CRE Women’s Health in Reproductive Life (WHiRL).

ESA Novartis Award

The ESA-Novartis Junior Scientist Award is given for the best presentation at the Annual Scientific Meeting by an advanced trainee or a person enrolled for a higher degree (PhD, MD, FRACP).

Recipient: Bronia Harding-Davis

AWARD WINNERS



I am honoured to receive the ESA-Novartis Junior Scientist Award for my presentation titled “Central administration of activin A in male mice suppresses food intake in response to fasting and ghrelin”.

I would like to extend my sincerest gratitude to my supervisor, Dr Sarah Lockie, who not only assisted me through the duration of the project but encouraged me to submit an abstract to the ESA 2021 Annual Scientific Meeting and provided guidance on creating a conference presentation. I would also like to thank my co-supervisor Dr Kelly Walton and members of the Andrews and Harrison/Walton labs for their guidance throughout the project.

My research was conducted as part of the Masters of Biomedical and Health Science at Monash University, which provided a wonderful research experience courtesy of Professor Ramesh Rajan and Dr Pippa Iva.

My project assessed reduced ghrelin sensitivity in a mouse model of cancer cachexia, looking specifically at whether the growth factor, activin A interacts with ghrelin to reduce feeding. For the first time,

we showed that activin A, delivered directly into the lateral ventricle, significantly reduces both fasted refeeding and ghrelin induced feeding within one hour of administration. As activin is elevated in chronic conditions such as cancer, this may explain some of the appetite loss occurring in cachexia.

Thank you, ESA, for allowing me the opportunity to present my work at my first scientific conference. This was a wonderful experience for me as an emerging scientist and I am extremely grateful just to have been selected to present, let alone receive this award. I hope in future, I will be able to attend in person.

ESA Australian Women in Endocrinology Outstanding Abstract Award

This award recognises outstanding scientific abstracts submitted by women to the ESA Annual Scientific Meeting. This award is supported by the Australasian Branch of Women in Endocrinology.

Recipient: Ayanthi Wijewardene



Thank you to the Endocrine Society of Australia for the Australian Women in Endocrinology Outstanding Abstract award and the ESA higher degree scholarship. It is an honour to receive these

prestigious awards. I was also privileged to present my research as a Bryan Hudson Finalist at this year's ESA annual scientific meeting.

My PhD focus is on personalising thyroid cancer management for patients with differentiated thyroid cancer. Our research identified factors outside of current international guidelines that are associated with recurrence and synchronous metastasis.

Combining the ATA 2015 initial risk stratification with these additional risk factors we developed an algorithm to guide personalised radioactive iodine treatment choices. Subsequently, we translated our algorithm into a novel online clinical support tool, providing clinicians with easy to access, evidence based radioactive treatment recommendations.

I would like to thank my supervisors Professor Clifton-Bligh, Dr Tacon and Dr Gild for their endless support and guidance. I would also like to acknowledge the support of

the Nuclear medicine, Endocrine surgical, Anatomical pathological and Endocrine departments at Royal North Shore Hospital for their collaboration on this project. Thank you again to ESA for the invaluable support of my research.

ESA Australian Women in Endocrinology Outstanding Abstract Award

This award recognises outstanding scientific abstracts submitted by women to the ESA Annual Scientific Meeting. This award is supported by the Australasian Branch of Women in Endocrinology.

Recipient: Dr Caroline Jung



I was honoured to receive the Australasian Women in Endocrinology (AWE) award for an Oral presentation at the Endocrine Society of Australia (ESA) conference in 2021. This research was a multicentre study

investigating the accuracy of the 4-mg intravenous dexamethasone suppression test (IVDST) in the diagnosis of Cushing's syndrome over a 25 year period.

Our work demonstrated that IVDST has a high sensitivity for the diagnosis of Cushing's syndrome and highlighted the utility of this test in patients of abnormal or discordant screening tests.

After I had completed Doctor of Philosophy (PhD) degree in 2011 on the hypothalamic-pituitary-adrenal (HPA) axis, I have been working as a clinical Endocrinologist at St Vincent's Hospital, Royal Women's Hospital and Royal Victorian Eye and Hospital in Melbourne.

I wish to thank the ESA for the Seed Grant in 2019 which gave me the impetus to restart clinical research on the IVDST and other projects related to the HPA axis. I am grateful to the collaborators of the IVDST project, Maresa Derbyshire, Niyati Jauhar, Duncan Topliss, Reetu Gogna, John Burgess and Warrick Inder.

ESA Australian Women in Endocrinology Outstanding Abstract Award

This award recognises outstanding scientific abstracts submitted by women to the ESA Annual Scientific Meeting. This award is supported by the Australasian Branch of Women in Endocrinology.

Recipient: Jennifer Chen



I am honoured to have been selected to be one of four recipients of the Australian Women in Endocrinology Outstanding Abstract Award for my presentation titled “Ablation of normal vitamin D signalling

impairs skeletal muscle regeneration in mice”.

I sincerely thank the Endocrine Society of Australia and the Australasian Branch of Women in Endocrinology (AWE) and am grateful for this award which has been well received as warm encouragement by a junior researcher such as myself that is starting on the path of a career in basic and translational research.

The incidence of vitamin D deficiency is common amongst elderly persons, and surprisingly is also high in athletes from various countries including Australia. Low serum vitamin D levels is associated with an increased risk of falls and the development of muscle weakness.

My study was a follow-up on our recent published work on myocyte-specific vitamin D receptor (mVDR) knockout mice. We showed that vitamin D signalling has direct, nonclassical action in skeletal muscle, modulating muscle function. Compared to the control group, myofibres in mVDR mice had more centralised nuclei. In addition, a larger proportion of mVDR myofibres

were angular in shape. Together, this was suggestive of a perturbed homeostatic state and ongoing remodelling.

In this study, satellite cell-specific vitamin D receptor (svDR) knockout mice were used to investigate whether muscle regeneration capacity would be diminished in the absence of normal vitamin D signalling. Notexin treated tibialis anterior (TA) muscle in the floxed control group were markedly heavier and had a greater number of centralised nuclei compared to notexin treated TA in svDR mice.

Our preliminary data suggests ablation of normal vitamin D signalling in satellite cells led to a delay in onset and slower progression of muscle repair after acute injury.

I would like to acknowledge and thank Professor Jenny Gunton for the opportunities and career support she has generously provided over the past few years. I also extend my thanks to Associate Professor Christian Girgis for his help with this project.

Bryan Hudson Clinical Endocrinology Award

The Bryan Hudson Clinical Endocrinology Award recognises the best clinical research presentation at the Annual Scientific Meeting by an active member of the Endocrine Society of Australia early in their career.

Recipient: Sarah Catford

AWARD WINNERS



I am thrilled to be the recipient of the 2021 Bryan Hudson Clinical Endocrinology Award for my presentation “Reproductive and metabolic health of young men conceived using ICSI”. Since its introduction for

male infertility, the use of intracytoplasmic sperm injection (ICSI) has increased. Concerns have intensified about the heritability of infertility, the effects of poor-quality sperm on offspring health, and the potential for the ICSI technique to induce epigenetic changes with long-term health effects.

In this study, we compared the reproductive and metabolic health of ICSI-conceived men aged 18-25 to IVF-conceived and spontaneously-conceived (SC) controls. Controls were sourced from prior studies including the WA Raine cohort. A subgroup analysis compared ICSI-conceived men whose fathers had spermatogenic failure (STF-ICSI) to ICSI-conceived men whose fathers had an obstructive cause of infertility (OBS-ICSI) and presumed normal spermatogenesis, to isolate the effects of paternal infertility. STF-ICSI-conceived men were also compared to IVF-conceived and SC controls.

ICSI-conceived men including STF-ICSI-conceived men had no evidence of poorer reproductive health compared to SC controls derived from


a general population cohort. Reproductive parameters of STF-ICSI- and OBS-ICSI-conceived men were similar. There was no correlation in any of the semen parameters between ICSI-conceived men and their fathers.

Regarding metabolic health, ICSI-conceived men, compared with SC controls, had higher resting diastolic blood pressure and HOMA-IR scores. Similar differences were observed between STF-ICSI-conceived men and SC controls. Differences in biochemical analysis and characteristics of study groups may explain these findings, but their potential significance should not be overlooked. The metabolic health of ICSI-conceived men and IVF-conceived controls was comparable. Metabolic parameters were also similar between STF-ICSI- and OBS-ICSI-conceived men.

Results of this study, the largest to date globally, are reassuring and contribute to our current understanding of the safety of ICSI, in particular the reproductive and metabolic health of ICSI-conceived men. Further studies are needed to confirm these data and follow-up of pregnancy outcomes will be important to confirm reproductive health findings.

I am very grateful to the ESA for the opportunity to present my research. I would like to thank my PhD supervisors, Professor Rob McLachlan, Professor Moira O’Bryan and Professor Jane Halliday for their support and enthusiasm.

ESA Journals




Journal of Endocrinology

The *Journal of Endocrinology* publishes original research articles, reviews and science guidelines. Its focus is on endocrine physiology and metabolism, including hormone secretion, hormone action and biological effects. The journal publishes basic and translational studies at the organ, tissue and whole organism level.

ESA members receive a 25% discount on colour figure and data charges.

Website: <http://joe.bioscientifica.com>



Endocrinology Related Cancer

Endocrine Related Cancer provides a unique international forum for the publication of original articles describing novel, cutting-edge basic laboratory, translational and clinical investigations of human health and disease. Endocrine-Related Cancer focusses on endocrine neoplasias and hormone-dependent cancers; and for the publication of authoritative review articles in these topics. Members of ESA receive a 25% discount on colour and data charges.


Website: erc.bioscientifica.com



Australian Endocrinology Research Review

Australian Endocrinology Research Review is an independent medical update, with each edition featuring 10 key medical articles from global endocrinology journals with commentary from Professor Cres Eastman, Professor Duncan Topliss and Associate Professor Michael Hooper, on why it matters to Australian practice. It is free to receive for all Australian health professionals and is delivered by email as a PDF attachment.

Website: <http://www.researchreview.com.au/au/Clinical-Area/Internal-Medicine/Diabetes-Obesity/Endocrinology.aspx>




Clinical Endocrinology

ESA has partnered with the Journal *Clinical Endocrinology*, adopting it as the official journal of ESA. ESA members have free electronic access to this journal, and free access to the journal's virtual issue of Clinical Questions.

Clinical Endocrinology publishes papers and reviews monthly, which focus on the clinical aspects of endocrinology, including the clinical application of molecular endocrinology. It features reviews, original papers, commentaries, cases of the month, book reviews and letters to the editor. *Clinical Endocrinology* is essential reading not only for those engaged in endocrinological research but also for those involved primarily in clinical practice.

To access the journal: Use the member log-in on the homepage: <http://www.endocrinesociety.org.au/> | Go to the Journals tab and select Clinical Endocrinology.



Journal of Molecular Endocrinology

The *Journal of Molecular Endocrinology* is the only society-owned journal dedicated to molecular endocrinology.

The journal focuses on molecular and cellular mechanisms in endocrinology, including: gene regulation, cell biology, signalling, mutations, transgenics, hormone-dependant cancers, nuclear receptors, and omics. Basic and pathophysiological studies at the molecule and cell level are considered, as well as human sample studies where this is the experimental model of choice. Technique studies including 'omics, CRISPR or gene editing are also encouraged.

ESA endorses *Journal of Molecular Endocrinology* entitling the ESA membership to a 25% discount on colour figure charges.

Website: jme.bioscientifica.com



Endocrinology,
Diabetes & Metabolism
CASE REPORTS

Endocrinology, Diabetes & Metabolism Case Reports

Endocrinology, Diabetes & Metabolism Case Reports publishes case reports on common and rare conditions in all areas of clinical endocrinology, diabetes and metabolism.

Articles include clear learning points which readers can use to inform medical education or clinical practice. This resource enables practitioners to communicate findings, share knowledge and convey medical experiences efficiently and effectively.

Members of ESA receive a 25% discount on the article publication charge when their paper is published in EDM Case Reports.

Website: <https://edm.bioscientifica.com/>

Upcoming ESA Events



ESA Seminar 2022

29 April - 1 May
2022

Launceston,
Tasmania



ESA Clinical Weekend 2022

11- 13 November
2022

Christchurch, New
Zealand



ESA-SRB-APEG-NZSE ASM 2022

12- 16 November
2022

Christchurch, New
Zealand





ESA Facebook



ESA Twitter

2021

ESA Annual Report



www.endocrinesociety.org.au
e: ijohnson@endocrinesociety.org.au
145 Macquarie Steet, Sydney, NSW 2000



2021

ESA Annual Report